Skip to content

Study · Not a test of the peptide alone · 1988

2 results

Delayed release formulation of the somatostatin analog RC-160 inhibits the growth hormone (GH) response to GH-releasing factor-(1-29)NH2 and decreases elevated prolactin levels in rats.

Bokser L, Schally AV

Endocrinology1 Oct 1988Cited by 7 (Europe PMC)

PMID2901338 (opens in a new tab)DOI10.1210/endo-123-4-1735 (opens in a new tab)PepBankPUB-02901338
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Sermorelin.

  1. 01AnimalNot a test of Sermorelin aloneAnimal study (in vivo)Efficacy outcome

    In male rats given vehicle, GRF-(1-29)NH2 increased GH levels at all four times tested.

    In plain wordsIn rats given vehicle, GH-releasing factor raised growth hormone levels at each time tested.

    Peptide
    Sermorelin
    Outcome
    IncreaseGH level after GRF-(1-29)NH2 in vehicle-treated rats
    Study

    ratn: not reported in source

    Male rats anesthetized with pentobarbital
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    GRF administration increased GH levels at the four times tested (P less than 0.01) in the control group injected with vehicle
    1 context sentence
    Summary · context
    Male rats anesthetized with pentobarbital were injected iv with 2.5 micrograms/kg BW GRF-(1-29)NH2 or saline.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  2. 02AnimalNot a test of Sermorelin aloneAnimal study (in vivo)Efficacy outcome

    In male rats, RC-160 microcapsules inhibited the GH response to GRF-(1-29)NH2 for more than 96 h.

    In plain wordsIn rats, a slow-release somatostatin analog blocked the growth hormone response to GH-releasing factor for over 96 hours.

    Peptide
    Sermorelin
    Outcome
    DecreaseGH response to GRF-(1-29)NH2 with RC-160 microcapsules
    Study

    ratn: not reported in source

    Male rats anesthetized with pentobarbital
    Comparator
    Vehicle
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    while RC-160 microcapsules inhibited the GH response for more than 96 h (P less than 0.01).
    1 context sentence
    Summary · context
    Male rats anesthetized with pentobarbital were injected iv with 2.5 micrograms/kg BW GRF-(1-29)NH2 or saline.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.